Compare metabolites in 2 of these studies:
Study A:   Study B:  

List of Studies ( Metabolite:2-Octenedioic acid)

Study_idAnalysis_idStudy_titleSourceSpeciesDiseaseInstituteAnalysis Type
ST004194 AN006967 PfK13-associated artemisinin resistance slows drug activation and enhances antioxidant defence, which can be overcome with sulforaphane Cultured cells Plasmodium falciparum Malaria Monash University LC-MS
ST004153 AN006895 Multi-omics Study of Small Intestine Adaptation After Total Colectomy in a Rat model Feces Rat Shanghai Jiao Tong University LC-MS
ST003880 AN006373 Untargeted metabolome analysis of control and disease intervertebral disc tissue Tissue Human Bone disease Ganga Orthopaedic Research and Education Foundation LC-MS
ST003639 AN005976 Multilevel Plasticity and Altered Glycosylation Drive Aggressiveness in Hypoxic and Glucose-Deprived Bladder Cancer Cells Cultured cells Human Cancer Portuguese Oncology Institute of Porto (IPO-Porto) LC-MS
ST003565 AN005858 Metaboloomics analysis of the antimalarial compound WEHI-1888504 (aka compound 59) in Plasmodium falciparum (3D7) infected red blood cells Cultured cells Plasmodium falciparum Malaria Monash University LC-MS
ST003521 AN005783 Metabolic Profiling Unveils Enhanced Antibacterial Synergy of Polymyxin B and Teixobactin against Multi-Drug Resistant Acinetobacter baumannii Bacterial cells Acinetobacter baumannii Bacterial infection Monash University LC-MS
ST003408 AN005593 Untargeted analysis of urine samples in a Longitudinal analysis of environmental exposures in pregnancy. Urine Human Baylor College of Medicine LC-MS
ST003179 AN005222 Property and Activity Refinement of Dihydroquinazolinone-3-carboxamides as Orally Efficacious Antimalarials that Target PfATP4 Plasmodium cells Plasmodium falciparum Malaria Monash University LC-MS
ST003160 AN005185 New class of heterospirocyclic compounds present strong and rapid activity against artemisinin- and multidrug-resistant P. falciparum parasites Plasmodium cells Plasmodium falciparum Malaria Monash University LC-MS
ST003053 AN005006 Providing insight into the mechanism of action of Cationic Lipidated Oligomers (CLOs) using metabolomics Bacterial cells Staphylococcus aureus Bacterial infection Monash University LC-MS
ST003053 AN005007 Providing insight into the mechanism of action of Cationic Lipidated Oligomers (CLOs) using metabolomics Bacterial cells Staphylococcus aureus Bacterial infection Monash University LC-MS
ST003036 AN004978 Identifying and mathematically modeling the time-course of extracellular metabolic markers associated with resistance to ceftolozane/tazobactam in Pseudomonas aeruginosa - Part 2 Bacterial cells Pseudomonas aeruginosa Bacterial infection Monash Institute of Pharmaceutical Sciences LC-MS
ST001788 AN002899 β-Adrenergic regulation of metabolism in macrophages (part-IV) Macrophages Human Monash University LC-MS
ST001788 AN002900 β-Adrenergic regulation of metabolism in macrophages (part-IV) Macrophages Human Monash University LC-MS
ST001549 AN002581 β-Adrenergic regulation of metabolism in macrophages (part-III) Macrophages Human Monash University LC-MS
ST001548 AN002579 β-Adrenergic regulation of metabolism in macrophages (part-II) Macrophages Human Monash University LC-MS
ST001547 AN002577 β-Adrenergic regulation of metabolism in macrophages Macrophages Human Monash University LC-MS
ST001276 AN002117 Development and Characterisation of a Novel Class of Aroyl Guanidine Containing Anti-Trypanosomal Compounds Cultured cells Trypanosoma brucei Sleeping sickness Monash University LC-MS
ST001274 AN002115 Metabolomics-based profiling of the mode of action of Pathogen Box compounds in Trypanosoma brucei (part-I) Cultured cells Trypanosoma brucei Sleeping sickness Monash University LC-MS
ST001175 AN001951 Multi-omics analysis demonstrates unique mode of action of a potent new antimalarial compound, JPC-3210, against Plasmodium falciparum Plasmodium cells Plasmodium falciparum Malaria Monash University LC-MS
ST000539 AN000819 Metabolomics-based elucidation of active metabolic pathways in erythrocytes and HSC-derived reticulocytes (part II) Cells Human Monash University LC-MS
ST000444 AN000695 Preconcentration of organic solutes in urine by bubble bursting Urine Human V.I. Kulakov Research Center for Obstetrics, Gynecology and Perinatology LC-MS
ST000422 AN000667 Type 1 Diabetes good glycemic control and controls samples Blood Human Diabetes Mayo Clinic LC-MS
ST000422 AN000669 Type 1 Diabetes good glycemic control and controls samples Blood Human Diabetes Mayo Clinic LC-MS
ST000421 AN000663 ms3076 T1D poor glycemic control and control samples Blood Human Diabetes Mayo Clinic LC-MS
ST000403 AN000643 Metabolomics-based elucidation of active metabolic pathways in erythrocytes and HSC-derived reticulocytes Cells Human Monash Institute of Pharmaceutical Sciences LC-MS
ST000047 AN000081 Identification of altered metabolic pathways in Alzheimer's disease, mild cognitive impairment and cognitively normals using Metabolomics (CSF) Cerebrospinal fluid Human Alzheimers disease Mayo Clinic LC-MS
ST000046 AN000076 Identification of altered metabolic pathways in Alzheimer's disease, mild cognitive impairment and cognitively normals using Metabolomics (plasma) Blood Human Alzheimers disease Mayo Clinic LC-MS
ST000046 AN000077 Identification of altered metabolic pathways in Alzheimer's disease, mild cognitive impairment and cognitively normals using Metabolomics (plasma) Blood Human Alzheimers disease Mayo Clinic LC-MS
  logo